Literature DB >> 8459205

Molecular characterization of the humoral responses to Cryptococcus neoformans infection and glucuronoxylomannan-tetanus toxoid conjugate immunization.

J Mukherjee1, A Casadevall, M D Scharff.   

Abstract

The molecular characteristics of the humoral immune response to a serotype A Cryptococcus neoformans infection were compared with the response elicited by a cryptococcal glucuronoxylomannan-tetanus toxoid (GXM-TT) conjugate. Anticryptococcal monoclonal antibodies (mAbs) isolated from both responses have previously been shown to recognize the same antigenic determinant of cryptococcal GXM. Southern blot and sequence analyses indicate that the hybridomas isolated from each response arose from only a few precursor B cells. All the mAbs generated from the infected and GXM-TT conjugate-immunized mice utilize the same VH7183 family member: JH2/JH4, v kappa 5.1, and J kappa 1; mAbs generated by different B cells had complementarity-determining region 3's (CDR3s) composed of seven amino acids with a common sequence motif. Thus, the molecular analysis of these anticryptococcal mAb-producing hybridomas indicated that the response to both cryptococcal infection and conjugate immunization was oligoclonal and highly restricted with regard to immunoglobulin gene utilization. The GXM-TT conjugate primarily stimulated isotype switching and clonal proliferation, and did not result in hybridomas expressing additional immunoglobulin repertoires. The mAbs from both responses had a number of replacement mutations at the 5' end of CDR2 that appear to be the result of antigen-driven selection. Somatic mutation also resulted in altered epitope specificity for one mAb, 13F1. Passive administration of representative mAbs from different clones generated in response to the GXM-TT conjugate prolonged survival of lethally infected mice.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8459205      PMCID: PMC2190969          DOI: 10.1084/jem.177.4.1105

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  73 in total

1.  Strain-dependent restricted VH and VL usage by anti-bacterial levan monoclonal antibodies.

Authors:  C M Boswell; D C Irwin; J Goodnight; K E Stein
Journal:  J Immunol       Date:  1992-06-15       Impact factor: 5.422

2.  Antibodies elicited by a Cryptococcus neoformans-tetanus toxoid conjugate vaccine have the same specificity as those elicited in infection.

Authors:  A Casadevall; J Mukherjee; S J Devi; R Schneerson; J B Robbins; M D Scharff
Journal:  J Infect Dis       Date:  1992-06       Impact factor: 5.226

3.  Mitotic recombination in germ cells generated two major histocompatibility complex mutant genes shown to be identical by RNA sequence analysis: Kbm9 and Kbm6.

Authors:  J Geliebter; R A Zeff; R W Melvold; S G Nathenson
Journal:  Proc Natl Acad Sci U S A       Date:  1986-05       Impact factor: 11.205

4.  Antigenic variation within serotypes of Cryptococcus neoformans detected by monoclonal antibodies specific for the capsular polysaccharide.

Authors:  C Spiropulu; R A Eppard; E Otteson; T R Kozel
Journal:  Infect Immun       Date:  1989-10       Impact factor: 3.441

5.  Cryptococcus neoformans serotype A glucuronoxylomannan-protein conjugate vaccines: synthesis, characterization, and immunogenicity.

Authors:  S J Devi; R Schneerson; W Egan; T J Ulrich; D Bryla; J B Robbins; J E Bennett
Journal:  Infect Immun       Date:  1991-10       Impact factor: 3.441

6.  Monoclonal antibody based ELISAs for cryptococcal polysaccharide.

Authors:  A Casadevall; J Mukherjee; M D Scharff
Journal:  J Immunol Methods       Date:  1992-09-18       Impact factor: 2.303

7.  Nonencapsulated Variant of Cryptococcus neoformans I. Virulence Studies and Characterization of Soluble Polysaccharide.

Authors:  T R Kozel; J Cazin
Journal:  Infect Immun       Date:  1971-02       Impact factor: 3.441

8.  Somatic mutation in a cultured mouse myeloma cell affects antigen binding.

Authors:  W D Cook; S Rudikoff; A M Giusti; M D Scharff
Journal:  Proc Natl Acad Sci U S A       Date:  1982-02       Impact factor: 11.205

9.  Anti-DNA antibodies from autoimmune mice arise by clonal expansion and somatic mutation.

Authors:  M Shlomchik; M Mascelli; H Shan; M Z Radic; D Pisetsky; A Marshak-Rothstein; M Weigert
Journal:  J Exp Med       Date:  1990-01-01       Impact factor: 14.307

10.  Subclass restriction of murine antibodies. II. The IgG plaque-forming cell response to thymus-independent type 1 and type 2 antigens in normal mice and mice expressing an X-linked immunodeficiency.

Authors:  J Slack; G P Der-Balian; M Nahm; J M Davie
Journal:  J Exp Med       Date:  1980-04-01       Impact factor: 14.307

View more
  66 in total

1.  Enhancement of nitric oxide synthesis by macrophages represents an additional mechanism of action for amphotericin B.

Authors:  N Mozaffarian; J W Berman; A Casadevall
Journal:  Antimicrob Agents Chemother       Date:  1997-08       Impact factor: 5.191

2.  Radial mass density, charge, and epitope distribution in the Cryptococcus neoformans capsule.

Authors:  Michelle E Maxson; Ekaterina Dadachova; Arturo Casadevall; Oscar Zaragoza
Journal:  Eukaryot Cell       Date:  2006-11-17

3.  Depletion of complement has distinct effects on the primary and secondary antibody responses to a conjugate of pneumococcal serotype 14 capsular polysaccharide and a T-cell-dependent protein carrier.

Authors:  Samuel T Test; Joyce K Mitsuyoshi; Yong Hu
Journal:  Infect Immun       Date:  2005-01       Impact factor: 3.441

4.  Effects of antifungal interventions on the outcome of experimental infections with phenotypic switch variants of Cryptococcus neoformans.

Authors:  Bettina C Fries; Emily Cook; Xiabo Wang; Arturo Casadevall
Journal:  Antimicrob Agents Chemother       Date:  2005-01       Impact factor: 5.191

5.  Immunogenicity and efficacy of Cryptococcus neoformans capsular polysaccharide glucuronoxylomannan peptide mimotope-protein conjugates in human immunoglobulin transgenic mice.

Authors:  Robert W Maitta; Kausik Datta; Andrew Lees; Shelley Sims Belouski; Liise-anne Pirofski
Journal:  Infect Immun       Date:  2004-01       Impact factor: 3.441

6.  Capsular localization of the Cryptococcus neoformans polysaccharide component galactoxylomannan.

Authors:  Magdia De Jesus; André Moraes Nicola; Marcio L Rodrigues; Guilhem Janbon; Arturo Casadevall
Journal:  Eukaryot Cell       Date:  2008-10-24

7.  Variable efficacy of passive antibody administration against diverse Cryptococcus neoformans strains.

Authors:  J Mukherjee; M D Scharff; A Casadevall
Journal:  Infect Immun       Date:  1995-09       Impact factor: 3.441

8.  Improved survival of mice deficient in secretory immunoglobulin M following systemic infection with Cryptococcus neoformans.

Authors:  Krishanthi S Subramaniam; Kausik Datta; Matthew S Marks; Liise-Anne Pirofski
Journal:  Infect Immun       Date:  2009-11-09       Impact factor: 3.441

9.  Characterization of a murine monoclonal antibody to Cryptococcus neoformans polysaccharide that is a candidate for human therapeutic studies.

Authors:  A Casadevall; W Cleare; M Feldmesser; A Glatman-Freedman; D L Goldman; T R Kozel; N Lendvai; J Mukherjee; L A Pirofski; J Rivera; A L Rosas; M D Scharff; P Valadon; K Westin; Z Zhong
Journal:  Antimicrob Agents Chemother       Date:  1998-06       Impact factor: 5.191

10.  Antibody action after phagocytosis promotes Cryptococcus neoformans and Cryptococcus gattii macrophage exocytosis with biofilm-like microcolony formation.

Authors:  Mauricio Alvarez; Carolyn Saylor; Arturo Casadevall
Journal:  Cell Microbiol       Date:  2008-04-01       Impact factor: 3.715

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.